ROSIGLITAZONE MALEATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rosiglitazone Maleate, and what generic alternatives are available?
Rosiglitazone Maleate is a drug marketed by Ani Pharms, Teva Pharms Usa, and Teva. and is included in three NDAs.
The generic ingredient in ROSIGLITAZONE MALEATE is metformin hydrochloride; rosiglitazone maleate. There are forty-nine drug master file entries for this compound. Additional details are available on the metformin hydrochloride; rosiglitazone maleate profile page.
Summary for ROSIGLITAZONE MALEATE
US Patents: | 0 |
Applicants: | 3 |
NDAs: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 75 |
Clinical Trials: | 22 |
Patent Applications: | 3,108 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ROSIGLITAZONE MALEATE at DailyMed |
Recent Clinical Trials for ROSIGLITAZONE MALEATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Mutual Pharmaceutical Company, Inc. | Phase 1 |
Cetero Research, San Antonio | Phase 1 |
GlaxoSmithKline | Phase 1 |